Affordable Access

Publisher Website

Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia.

  • Tella, Sri Harsha1, 2
  • Amalou, Hayet3
  • Wood, Bradford J3
  • Chang, Richard4
  • Chen, Clara C5
  • Robinson, Cemre2
  • Millwood, Michelle2
  • Guthrie, Lori C2
  • Xu, Sheng3
  • Levy, Elliot3
  • Krishnasamy, Venkatesh3
  • Gafni, Rachel I2
  • Collins, Michael T2
  • 1 Department of Endocrinology, Diabetes and Metabolism, National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.
  • 2 Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA.
  • 3 Interventional Radiology and Center for Interventional Oncology, National Institutes of Health (NIH), Bethesda, MD, USA.
  • 4 Endocrine and Venous Services Section, Radiology and Imaging Sciences, National Institutes of Health (NIH), Bethesda, MD, USA.
  • 5 Nuclear Medicine Section, National Institutes of Health (NIH), Bethesda, MD, USA.
Published Article
Journal of Bone and Mineral Research
Wiley (John Wiley & Sons)
Publication Date
Nov 01, 2017
DOI: 10.1002/jbmr.3219
PMID: 28718983


Tumor-induced osteomalacia (TIO) is a debilitating paraneoplastic condition caused by small phosphaturic mesenchymal tumors (PMTs) that secrete large amounts of the phosphate-regulating and vitamin D-regulating hormone, FGF23. Tumor removal results in cure. However, because of high perioperative comorbidity, either from tumor location or host factors, surgery is sometimes not an option. Tumor destruction via cryoablation may be an effective option for inoperable PMTs. Three subjects with a confirmed diagnosis of TIO were studied. All three underwent cryoablation of suspected PMTs rather than surgery due to significant medical comorbidities or challenging anatomical location. Subject 3 had tumor embolization 24 hours prior to cryoablation because of the size and hypervascularity of the tumor. The success of the tumor cryoablation was defined by normalization of serum phosphate and FGF23. Cryoablation resulted in a rapid decrease in plasma intact FGF23 by 24 hours postprocedure in all three subjects (0, 2, and 9 pg/mL, respectively) with normalization of blood phosphate by postprocedure day 3. Three-day renal tubular reabsorption of phosphate increased to 76%, 94%, and 95.2%, respectively; 1, 25(OH)2 vitamin D increased to 84, 138, and 196 pg/ml, respectively. All three had dramatic clinical improvement in pain and weakness. Two subjects tolerated the procedure well with no complications; one had significant prolonged procedure-related localized pain. Although surgery remains the treatment of choice, cryoablation may be an effective, less invasive, and safe treatment for patients with difficult to remove tumors or who are poor surgical candidates. © 2017 American Society for Bone and Mineral Research.

Report this publication


Seen <100 times